Skip to main content
TipRanks
Go Ultimate75% OFF

AFT Pharmaceuticals Ltd. (AFT) AI Stock Analysis

NZ:AFT

AFT Pharmaceuticals Ltd.

(NZX:AFT)

Select Model
Rating:54Neutral
Price Target:NZD 4.50â–¼(-1.96% Downside)
Action:initiatedcoverage
Date:10/05/26

The score is primarily held back by the sharp downturn in the latest cash flow results and related balance-sheet risk (higher debt alongside negative free cash flow), despite strong revenue growth and stable gross margins. Technical indicators are broadly neutral and valuation appears relatively expensive, which limits upside without a clear improvement in cash generation and profitability.

Positive Factors
Strong revenue growthA sustained rise in revenue across five annual periods indicates expanding product adoption and international commercial reach. The latest acceleration, together with growth across territories, provides a stronger foundation for reinvestment, operating leverage, and continued scale over the next several quarters.
Negative Factors
Negative cash generationThe reversal to negative operating and free cash flow weakens cash conversion and increases reliance on external financing or balance-sheet resources. Until generation normalises, AFT has less flexibility to fund product development, absorb execution setbacks, or pursue growth while maintaining financial resilience.

AFT Pharmaceuticals Ltd. (AFT) vs. SPDR S&P 500 ETF (SPY)

-10%0%10%20%30%40%NZ:AFT+25.72%SPY+4.27%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
NZD 370.21M
Dividend Yield
0.64%
Average Volume (3M)
20.07K
Price to Earnings (P/E)
32.5
Beta (1Y)
-0.09
Revenue Growth
22.44%
EPS Growth
23.14%
Country
NZ
Employees
126
Sector
Healthcare
Sector Strength
51
Industry
Drug Manufacturers - Specialty & Generic

AFT Pharmaceuticals Ltd. Business Overview & Revenue Model

Company Description

AFT Pharmaceuticals, along with its subsidiaries, focuses on the creation and distribution of pharmaceutical products across New Zealand, Australia, Asia, and other global markets. Their extensive product range addresses a variety of health categorie...

How the Company Makes Money

AFT primarily makes money by commercialising pharmaceutical products and earning revenue from selling those products into various markets. Key revenue streams typically include: (1) Direct product sales where AFT markets and distributes its own brand...

AFT Pharmaceuticals Ltd. Financial Statement Overview

Summary

Strong multi-year revenue growth and resilient gross margins are positives, but the latest period shows meaningful deterioration in cash generation (negative operating and free cash flow) alongside margin compression and a step-up in total debt, increasing near-term financial risk.

Income Statement

72Positive

Balance Sheet

66Positive

Cash Flow

38Negative
Financial statement breakdown
BreakdownTTMMar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Income Statement
Total Revenue254.71M254.71M205.49M195.41M155.82M129.83M
Gross Profit110.55M110.55M89.19M88.27M72.16M61.30M
EBITDA28.85M28.55M21.52M27.72M20.40M21.12M
Net Income14.73M14.73M11.96M15.61M10.65M19.85M
Balance Sheet
Total Assets217.01M217.01M169.81M165.26M148.06M121.76M
Cash, Cash Equivalents and Short-Term Investments10.24M10.24M11.11M12.04M4.75M7.94M
Total Debt54.11M54.11M30.00M32.19M38.05M40.51M
Total Liabilities107.94M107.94M72.74M77.46M74.80M65.02M
Stockholders Equity110.28M110.28M97.64M87.80M73.27M56.74M
Cash Flow
Free Cash Flow-11.87M-11.87M6.22M16.02M-173.00K6.64M
Operating Cash Flow-11.75M-11.75M13.18M25.55M9.00M12.22M
Investing Cash Flow-9.76M-9.76M-6.95M-9.53M-9.18M-5.58M
Financing Cash Flow11.01M11.01M-6.81M-10.63M-6.98M-3.91M

AFT Pharmaceuticals Ltd. Technical Analysis

Technical Analysis SentimentPositive
Last Price4.59

Price Trends

50DMA4.48Positive
100DMA4.39Positive
200DMA4.00Positive

Market Momentum

MACD0.02Positive
RSI52.86Neutral
STOCH64.08Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NZ:AFT, the sentiment is Positive. The current price of 4.59 is above the 20-day moving average (MA) of 4.59, above the 50-day MA of 4.48, and above the 200-day MA of 4.00, indicating a bullish trend. The MACD of 0.02 indicates Positive momentum. The RSI at 52.86 is Neutral, neither overbought nor oversold. The STOCH value of 64.08 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for NZ:AFT.

AFT Pharmaceuticals Ltd. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

NZ:AFT against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
NZ:FPHNZ:FPH80OutperformNZD 29.03B61.6122.84%1.24%15.59%23.94%
NZ:EBONZ:EBO56NeutralNZD 4.54B16.717.99%5.69%16.36%5.52%
NZ:AFTNZ:AFT54NeutralNZD 485.57M32.4614.07%0.64%22.44%23.14%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
NZ:PEBNZ:PEB42NeutralNZD 341.52M-6.66-190.54%―-47.36%-3.79%
NZ:RUANZ:RUA42NeutralNZD 11.77M-2.60――70.82%41.04%
NZ:TRUNZ:TRU37UnderperformNZD 8.38M-2.58-75.57%―42.20%23.68%

* Healthcare Sector Average

Performance Comparison

-25%0%25%50%NZ:AFTNZ:EBONZ:FPHNZ:PEBNZ:TRUNZ:RUADec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
NZ:AFT and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
NZ:AFTAFT Pharmaceuticals Ltd.4.590.9325.38%
NZ:EBOEBOS Group Limited21.65-5.75-20.98%
NZ:FPHFisher & Paykel Healthcare Corporation Limited49.2912.5734.25%
NZ:PEBPacific Edge Limited0.260.0740.88%
NZ:TRUTruScreen Group Ltd.0.01-0.01-41.18%
NZ:RUARua Bioscience Ltd.0.03-0.00-3.70%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 05, 2026